Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Cerebral Amyloid Angiopathy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Cerebral Amyloid Angiopathy. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Cerebral Amyloid Angiopathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (2), Insel Gruppe AG, University Hospital Bern (1), Amydis Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Mediterranean Diet with Extra Virgin Olive Oil (other, 1 trial), followed by Mediterranean Diet with Walnuts, Low-Fat Control Diet.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Cerebral Amyloid Angiopathy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05734378

Prognosis of Cerebral Small Vessel Disease

Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the...

Sponsor: Insel Gruppe AG, University Hospital BernEnrolling: 9001 location
RECRUITINGNCT06933212

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 861 location
RECRUITINGNCT04204642

SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)

Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 5001 location
RECRUITINGPhase 2NCT05709314

A Study of AMDX-2011P in Participants With CAA

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral...

Sponsor: Amydis Inc.Enrolling: 251 location

Frequently Asked Questions

There are currently 4 clinical trials for Cerebral Amyloid Angiopathy, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Cerebral Amyloid Angiopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Cerebral Amyloid Angiopathy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.